Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8519263 | 0.86 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL7712869 | 0.83 | ALDH1A1 (0.50) | ALDH1A1ACE | |
| Ammonia Solution, Strong SCHEMBL28120022 | 0.80 | ALDH1A1 (0.48) | ALDH1A1ACE | |
| SCHEMBL43574 | 0.79 | EGLN1 (0.43) | ALDH1A1ACE | |
| SCHEMBL118947 | 0.79 | ALDH1A1 (0.50) | ALDH1A1 | |
| SCHEMBL876248 | 0.77 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL233404 | 0.77 | ALDH1A1 (0.68) | ALDH1A1 | |
| SCHEMBL1895096 | 0.77 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL3555482 | 0.77 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL27879493 | 0.76 | ACE (0.54) | ALDH1A1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945848-B2 | Chimeric inhibitor molecules of complement activation | OMEROS CORPORATION (US) | 2024-04-02 | — | — | US | disclosed |
| US-20230295252-A1 | CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION | OMEROS CORPORATION (US) | 2023-09-21 | — | — | US | disclosed |
| US-11453709-B2 | Chimeric inhibitor molecules of complement activation | OMEROS CORPORATION (US) | 2022-09-27 | — | — | US | disclosed |
| EP-3815708-A1 | CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION | Omeros Corporation (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20210009643-A1 | CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION | OMEROS CORPORATION (US) | 2021-01-14 | — | — | US | disclosed |
| EP-2542569-B1 | CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION | OMEROS CORP (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10752661-B2 | Chimeric inhibitor molecules of complement activation | OMEROS CORPORATION (US) | 2020-08-25 | — | — | US | disclosed |
| US-10294286-B2 | Chimeric inhibitor molecules of complement activation | OMEROS CORPORATION (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180273593-A1 | CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION | OMEROS CORPORATION (US) | 2018-09-27 | — | — | US | disclosed |
| US-9815876-B2 | Chimeric inhibitor molecules of complement activation | OMEROS CORPORATION (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170166616-A1 | CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION | RIGSHOSPITALET (DK) | 2017-06-15 | — | — | US | disclosed |
| US-9573984-B2 | Chimeric inhibitor molecules of complement activation | RIGSHOSPITALET (DK) | 2017-02-21 | — | — | US | disclosed |
| US-20150210743-A1 | CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION | OMEROS CORPORATION | 2015-07-30 | — | — | US | disclosed |
| US-20130217616-A1 | CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION | OMEROS CORPORATION | 2013-08-22 | — | — | US | disclosed |
| EP-2542569-A1 | CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION | Rigshospitalet (DK) | 2013-01-09 | — | — | EP | disclosed |
| WO-2011107591-A1 | CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION | RIGSHOSPITALET (DK) | 2011-09-09 | — | — | WO | disclosed |
| US-20060105948-A1 | GLP-2 derivatives | NOVO NORDISK A/S (DK) | 2006-05-18 | — | — | US | disclosed |
| EP-1608680-A2 | GLP-2 DERIVATIVES | NOVO NORDISK A/S (DK) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004085471-A2 | GLP-2 DERIVATIVES | NOVO NORDISK A/S (DK) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060105948-A1 | GLP-2 derivatives | GLP1R, GIPR, IAPP | ALDH1A1 4668/4885ACE 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.